Investment Thesis

Abbott Laboratories (ABT) is a BUY at current prices, trading at $103.96. The market is undervaluing Abbott's diverse portfolio across established pharmaceuticals, diagnostics, nutrition, and medical devices, especially considering its robust pipeline and ongoing innovations. This mispricing presents an attractive entry point for long-term investors, as the company is poised for sustainable growth driven by demographic trends and increased healthcare demands.

Competitive Moat

Abbott benefits from significant intangible assets, including strong brand recognition and a diverse portfolio that fosters customer loyalty across its product segments. The company's regulatory expertise provides substantial barriers to entry, ensuring a durable competitive advantage over the next 5-10 years. Key threats include emerging competitors in the diagnostics space, particularly from newer, agile players leveraging technology, and price competition within the generic pharmaceuticals segment.

Growth Engine

Future revenue growth for Abbott is driven by its extensive total addressable market (TAM) in diagnostics and medical devices, estimated to expand as global health demands rise. The company is well-positioned to capitalize on its advancements in point-of-care testing and diabetes care products, which are projected to see increased adoption. Furthermore, Abbott's investments in R&D for innovative therapies and technologies will provide organic growth opportunities, while strategic acquisitions could enhance its market share and product offerings in underpenetrated areas.